Rosenstock J, Yabe D, Cox D, Li J, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet 2026 Feb 26:S0140-6736(26)00202-3. doi: 10.1016/S0140-6736(26)00202.
PMID: 41765029